PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 22 December 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]
today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose securities are
admitted to trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from Abingworth Management Limited and
Abingworth LLP.
The above shareholders notified Ablynx that they have dropped below the 5%
threshold on 17 December 2015. They now have a combined holding of 2,632,150
Ablynx shares, representing 4.80% of the current 54,812,374 outstanding Ablynx
shares.
Abingworth LLP ("ALLP") acts as manager of Abingworth Bioventures ("ABV") V LP
and Abingworth Bioequities Master Fund Limited and exercises voting rights for
shares held by those funds. Abingworth Management Limited ("AML") acts as
manager of ABV IV LP and ABV IV Executives LP and has engaged ALLP to assist it
in the provision of fund management services for those funds. An investment
Committee comprised of the same individuals at ALLP effectively exercises voting
rights for funds managed by AML as well as funds managed by ALLP.
Full versions of all transparency notifications are available on Ablynx website,
under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of
Nanobodies(®), proprietary therapeutic proteins based on single-domain antibody
fragments, which combine the advantages of conventional antibody drugs with some
of the features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company has
approximately 40 proprietary and partnered programmes in development in various
therapeutic areas including inflammation, haematology, immuno-oncology, oncology
and respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm,
Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx(at)instinctif.com
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx(at)instinctif.com
Pdf version of the press release:
http://hugin.info/137912/R/1975115/722781.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via GlobeNewswire
[HUG#1975115]
Unternehmensinformation / Kurzprofil:
Datum: 22.12.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 441170
Anzahl Zeichen: 3930
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 383 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
